Sarepta Therapeutics to Announce Fourth Quarter & Full-Year 2016 Financial Results & Recent Corporate Developments on Februar...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, will report fourth quarter and full-year 2016 financial results after the NASDAQ Global Market closes on Tuesday, February 28, 2017. Subsequently, at 4:30 p.m., Eastern Time, Edward Kaye, M.D., Sarepta’s chief executive officer, Sandy Mahatme, Sarepta’s chief financial officer, and Bo Cumbo, Sarepta’s senior vice president of global commercial development will host a conference call to discuss fourth quarter and full-year financial results and to provide a corporate update.

The conference call may be accessed by dialing [phone] for domestic callers and [phone] for international callers. The passcode for the call is 73840094. Please specify to the operator that you would like to join the "Sarepta Fourth Quarter and Full-Year 2016 Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About SareptaSarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates. For more information, please visit us at www.sarepta.com.

Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our web site at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170215005620/en/

Media and Investors:Sarepta Therapeutics, Inc.Ian Estepan, [e-mail]2O GroupBrian Reid, [e-mail]